China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

This summary covers recent developments in health from the death tied to a cyberattack on Synnovis services in the UK, the Eli Lilly and Novo Nordisk rivalry in the weight-loss drug market in India, ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...